Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line EP chemotherapy with sequential apatinib for extensive-stage small cell lung cancer
ChiCTR-IPR-17010361Phase 4Not yet recruiting
- Sponsor
- The North Hospital of the Affiliated Hospital of Qingdao University
- Start
- Dec 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by The North Hospital of the Affiliated Hospital of Qingdao University. Primary endpoint: Progression-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
Rivoceranibcisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-17010361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010361.